Trial NCT03382574

Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy

This randomized pilot clinical trial studies how well denosumab works in BRCA1/2 mutations
carriers scheduled for risk-reducing salpingo-oophorectomy. Immunotherapy with denosumab, may
induce changes in body's immune system and may interfere with the ability of tumor cells to
grow and spread.

Intervention

Denosumab, Salpingo-Oophorectomy

Condition

BRCA1 Gene Mutation, BRCA2 Gene Mutation, Premenopausal

Investigators

Judy E. Garber, Kevin Holcomb, Powel H. Brown, Nadir Arber, Meghna S. Trivedi, Robert M. Wenham, Eitan Friedman

See list of participating sites